- Home
- VOXR vs OTLK Comparison
VOXR vs OTLK Comparison
Compare VOXR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- OTLK
- Stock Information
- Founded
- VOXR 2014
- OTLK 2010
- Country
- VOXR Canada
- OTLK United States
- Employees
- VOXR N/A
- OTLK N/A
- Industry
- VOXR Precious Metals
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VOXR Basic Materials
- OTLK Health Care
- Exchange
- VOXR Nasdaq
- OTLK Nasdaq
- Market Cap
- VOXR 151.7M
- OTLK 121.8M
- IPO Year
- VOXR N/A
- OTLK 2016
- Fundamental
- Price
- VOXR $2.71
- OTLK $6.32
- Analyst Decision
- VOXR Buy
- OTLK Strong Buy
- Analyst Count
- VOXR 1
- OTLK 7
- Target Price
- VOXR $3.00
- OTLK $48.20
- AVG Volume (30 Days)
- VOXR 185.6K
- OTLK 296.8K
- Earning Date
- VOXR 11-06-2024
- OTLK 12-20-2024
- Dividend Yield
- VOXR 1.76%
- OTLK N/A
- EPS Growth
- VOXR N/A
- OTLK N/A
- EPS
- VOXR N/A
- OTLK N/A
- Revenue
- VOXR $11,147,864.00
- OTLK N/A
- Revenue This Year
- VOXR $1.91
- OTLK N/A
- Revenue Next Year
- VOXR $8.94
- OTLK N/A
- P/E Ratio
- VOXR N/A
- OTLK N/A
- Revenue Growth
- VOXR N/A
- OTLK N/A
- 52 Week Low
- VOXR $1.70
- OTLK $4.61
- 52 Week High
- VOXR $3.24
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- VOXR 30.47
- OTLK 60.47
- Support Level
- VOXR $3.01
- OTLK $5.66
- Resistance Level
- VOXR $3.11
- OTLK $6.98
- Average True Range (ATR)
- VOXR 0.11
- OTLK 0.33
- MACD
- VOXR -0.04
- OTLK 0.14
- Stochastic Oscillator
- VOXR 10.92
- OTLK 67.96
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of over 60 royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.